Navigation Links
AspenBio Pharma Reports Second Quarter 2007 Results
Date:8/20/2007

tatements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including the ability to successfully complete the development of new products, execute agreements required to successfully advance the company's objectives, retain the scientific management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, fluctuations in sales volumes, and realization of intangible assets. Furthermore, APNB does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this news release should be considered in conjunction with the warnings and cautionary statements contained in APNB's recent filings with the SEC.

For more information contact:

AspenBio Pharma, Inc.

Gregory Pusey, Chairman

Tel 303-722-4008

Investor Relations:

Liolios Group, Inc.

Scott Liolios or Ron Both

Tel 949-574-3860

AspenBio Pharma, Inc.

Periods Ended June 30, (Unaudited)

Condensed Statements of Operations

(In thousands, except per Three Months Ended Six Months Ended

share data) 2007 2006 2007 2006

Sales $ 177 $ 112 $ 513 $ 348

Gross profit 30 55 195 178

Other revenue - fee - - - 50

Operating Expenses:

Selling, general and

administrative

(includes non cash

compensation of $217;

$135; $499 and $189) 632 466 1,358 936

Research and

development 544 301 839 612

Operating loss (1,147) (
'/>"/>

SOURCE AspenBio Pharma, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... HSP A has been found to be effectinve in improving yelds ... ... -- Nu-Tek BioSciences, LLC. ( www.nu-tekproducts.com ) is meeting the demand ... manufactured by Nutricepts, Inc. (Burnsville, Mn), is a high quality Soy ... HSP-A has been found to be especially effective in improving ...
(Date:12/15/2009)... one of three Department of Energy (DOE) bio-energy research ... protect its valuable intellectual property. , ... ... 2009 -- Surety, LLC , the leading provider ... that the Joint BioEnergy Institute (JBEI), one of three ...
(Date:12/15/2009)... Reportlinker.com announces that a new ... catalogue: ,, The Future of ... 2015, Pipeline Analysis and Reimbursement ... ,, Summary ,, The author ... of Orphan Diseases Therapeutics - Market Forecasts ...
(Date:12/15/2009)... Microscopy (AFM) have been developed and are opening up a ... The NeedleProbes’ cylindrical geometry enables researchers to measure surface ... all in a single force distance curve. , ... ... diameter NeedleProbes are enabling unique measurements at the ...
Breaking Biology Technology:Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 2Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 3Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 4Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 5Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 2Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 3Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 4Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 5Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 6Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 7Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 8Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 9Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 10Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 11Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 12Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 13Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 14Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 15Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 16Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 17Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 18New Constant Diameter NeedleProbes™ with Unique Ability to Measure Liquid Surface Properties by AFM 2New Constant Diameter NeedleProbes™ with Unique Ability to Measure Liquid Surface Properties by AFM 3
... Endo Pharmaceuticals Inc. (Nasdaq: ENDP ), ... results on February 27, 2009 and will host ... that day to discuss these results. David P. ... Chief Operating Officer and Blaine Davis, Vice President, Corporate ...
... ETHEX Corporation, a,subsidiary of KV Pharmaceutical (NYSE: KVa/KVb), ... on January 26, 2009, a nationwide,voluntary recall of ... dates) at a wholesale or a retail level ... manufactured under conditions that did not,sufficiently comply with ...
... 21, Inc. (Nasdaq: NXXI ), a developer and ... levels, improve cardiovascular health, enhance memory and address chronic joint ... of the market - on Thursday, February 5, 2009 for ... 2008. The Company has scheduled a conference call to review ...
Other Biology Technology:Endo Pharmaceuticals to Announce Fourth Quarter and 2008 Full-Year Financial Results on February 27, 2009 2ETHEX Corporation Issues Nationwide Voluntary Recall of Products 2ETHEX Corporation Issues Nationwide Voluntary Recall of Products 3ETHEX Corporation Issues Nationwide Voluntary Recall of Products 4ETHEX Corporation Issues Nationwide Voluntary Recall of Products 5ETHEX Corporation Issues Nationwide Voluntary Recall of Products 6Nutrition 21 to Report Second Quarter Fiscal Year 2009 Financial Results on Thursday, February 5, 2009 2
(Date:12/16/2009)... Knowledge and Innovation Community (Climate-KIC)" is a major initiative ... program brings together the expertise of world class partners ... Europe,s innovation capacity to meet the climate change challenge ... a new low-carbon society. In responding to this challenge, ... produce, distribute, and consume goods, and to how we ...
(Date:12/16/2009)... Getting the most out of every drop of water is a ... summers are hot and dry and vines have to be irrigated ... found that a significant portion of the water applied to the ... "We found that about 10 percent of the water that is ... have contact with the soil and vine roots," said Eve Hinckley, ...
(Date:12/16/2009)... superstitions and rituals can help them get psyched up ... drugs (NSAIDs), which many athletes gobble down before and ... good. , "These agents are treatments for the symptoms ... Warden, whose research at Indiana University focuses on musculoskeletal ... to exercise or train at a certain level, but ...
Breaking Biology News(10 mins):Innovation boost to tackle climate change 2Innovation boost to tackle climate change 3Lost water of the Napa Valley vineyards 2Lost water of the Napa Valley vineyards 3Lost water of the Napa Valley vineyards 4NSAIDs: Take 'em early and often when competing? Think again 2Marathon Health Expands Midwest Presence 53929 1Marathon Health Expands Midwest Presence 53929 2ALPCO Introduces a Mouse HMW and Total Adiponectin ELISA 13440 1ALPCO Introduces a Mouse HMW and Total Adiponectin ELISA 13440 2Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and 24200 Million Principal Amount of Convertib 13439 1Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and 24200 Million Principal Amount of Convertib 13439 2Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and 24200 Million Principal Amount of Convertib 13439 3
... Ohio and Michigan fruit and vegetable farms yield this ... eating choices of Latino migrant children for a Case ... will help migrant families understand why their children are ... to new interventions to combat this serious health issue., ...
... August 2008 - Disease Models & Mechanisms ( ... research and the use of model organisms to advance human ... is a highly anticipated biomedical research journal which officially ... at http://DMM.biologists.org . , DMM focuses on ...
... the world,s plant species rely on animals to transfer their ... pollinators is the bee, made up of about 30,000 species ... than half of the world,s flowering plants. In recent years, ... the U.S. and Europe has placed the health of ecosystems ...
Other Biology News:Case Western Reserve University study looks at keeping migrant workers' children healthy 2Building bridges between the clinic and the laboratory 2Saving our bees 2Saving our bees 3
... system uses the Adept CE 4100 high pressure ... UV/Visible detector for added flexibility and utra low ... alternative to a photodiode array detection and provides ... is required for method development and for monitoring ...
... This CLS number is a ... match Cornings product number. If showing ... the old Sigma-Aldrich number (E6152) or ... Comp Dim: H diam. 11.25 ...
... numbers of samples may be carried out using ... attention. System control and data processing is ... The elegant, powerful and very easy to ... 98 and 2000., The supplied detector is the ...
Mouse monoclonal antibody to QPCT - glutaminyl-peptide cyclotransferase (glutaminyl cyclase)...
Biology Products: